| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IQVIA Holdings, Inc.$167.77
-2.9 (-1.7%)
B 71Pipeline Score Tools & Services · Commercial
Market Cap
28.02 B
EPS
8.14
P/E Ratio
20.81 $
Value Trade
279.98 M
SEC Financials
Q1 2026Dilution Risk
Revenue
4.15 B
Operating CF
618.00 M
Total Assets
29.68 B
Total Liabilities
23.33 B
Equity
6.22 B
D/E Ratio
12,345
-1.28 %
Week
-5.85 %
1 Month
-0.24 %
3 Month
-22.77 %
6 Month
-29.26 %
5 Year
283.68 %
All Time
Cash Data
Cash Position
2.10 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
3.70 M
52 Week Range
136.41 - 247.05
% held by Insiders
0.98 %
% held by Institutions
100.6 %
Enterprise Value
42.11 B
Total Shares
169.70 M
Short %
2.96 %
Float Shares
160.54 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B71
Pipeline Score $20.0B
Pipeline ValueValuation Signal
23
Drugs Scored2.4x
rNPV / MCap Top 95%
Mid Cap (rank 46 of 905)
Percentile RankIQVIA Holdings, Inc. holds a solid B-grade pipeline (71/100), with $23.5B risk-adjusted pipeline value, led by Atezolizumab in Advanced Solid Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atezolizumab Small molecule | Non-Small Cell Lung Cancer | Phase 2 | NCT03976518 | 19% | $8.7B | COMPLETED | 43 | - | - | Feb 12, 2024 | - | Mar 1, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IQV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IQV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IQV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IQV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IQV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IQV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IQVStackAdapt Teams Up with IQVIA Digital’s MediaOS to Power Healthcare Advertising
StackAdapt has partnered with IQVIA Digital's MediaOS to enhance healthcare advertising efforts. This collaboration emphasizes the importance of privacy in advertising, aiming to provide more effective solutions for healthcare marketers. The integration of these technologies is expected to drive innovation in the sector.
Read more →IQVWiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
Wiley and IQVIA have collaborated to release a report focusing on the implications of artificial intelligence across the healthcare value chain. The report highlights both the potential benefits and challenges associated with AI integration in healthcare. Further details about the findings and recommendations are expected to be elaborated upon in subsequent communications.
Read more →IQVIQVIA Announces Offering of Senior Notes - June 3, 2026
IQVIA Holdings Inc. announced its intention to raise €950 million through a senior notes offering due in 2033. The proceeds will be utilized to refinance existing debt and cover related fees. The offering is contingent upon market conditions and other customary factors, highlighting potential risks involved.
Read more →IQVIQVIA Announces Offering of Senior Notes
IQVIA has announced an offering of senior notes, although specific details regarding the amount or purpose of the offering are not provided in the article. The announcement is part of the company's ongoing financial strategies. Further information may be released in subsequent communications.
Read more →IQVIQVIA CEO to Speak at Jefferies Global Healthcare Conference
IQVIA's CEO is scheduled to speak at the Jefferies Global Healthcare Conference. The event is expected to provide insights into the company's strategies and future directions. However, specific details about the topics to be discussed have not been disclosed.
Read more →IQVIQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
IQVIA and Kexing Biopharm have announced an expansion of their strategic collaboration. The partnership aims to enhance global biosimilar development by leveraging AI-enabled capabilities. This initiative is expected to streamline processes and improve efficiency in the biopharmaceutical sector.
Read more →IQVIQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
IQVIA's Board of Directors has approved a significant increase in its share repurchase authorization by $2 billion. This decision reflects the company's commitment to enhancing shareholder value. However, the article lacks detailed information on the implications or context surrounding this decision.
Read more →IQVIQVIA CFO to Speak at Bank of America Health Care Conference 2026
IQVIA's CFO is scheduled to speak at the upcoming Bank of America Health Care Conference in 2026. This event is anticipated to provide insights into the company's strategies and outlook. Further details about the conference agenda and topics of discussion have not been disclosed.
Read more →IQVIQVIA Reports First-Quarter 2026 Results
IQVIA has released its financial results for the first quarter of 2026. The report highlights the company's performance metrics and financial health. However, specific details regarding revenue, profit, or other financial indicators were not disclosed in the article.
Read more →IQVIQVIA to Announce First-Quarter 2026 Results on May 5, 2026
IQVIA Holdings Inc. will announce its first-quarter 2026 financial results on May 5, 2026, before the market opens. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Interested parties must register in advance to participate in the call.
Read more →IQVIQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
IQVIA has launched IQVIA.ai, a new AI platform designed to enhance decision-making and efficiency in life sciences. This platform integrates advanced analytics and automation, allowing organizations to streamline operations and improve research capabilities. The collaboration with NVIDIA has resulted in over 100 AI-related patents, showcasing IQVIA's commitment to innovation in healthcare. The initial release will target high-value use cases across various domains.
Read more →IQVIQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
IQVIA Holdings Inc. announced that CEO Ari Bousbib will speak at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. The presentation will be available via a live audio webcast on the IQVIA Investor Relations website. This event underscores IQVIA's role as a leader in clinical research and healthcare intelligence.
Read more →IQVIQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
IQVIA Holdings Inc. announced that its CFO, Mike Fedock, will speak at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. The event will include a live audio webcast available on the company's Investor Relations website. IQVIA is known for its commitment to healthcare intelligence and clinical research services.
Read more →IQVIQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
IQVIA has announced an agreement to acquire drug discovery assets from Charles River Laboratories, which includes five specialized sites for in vitro drug discovery. This acquisition aims to enhance IQVIA's end-to-end drug discovery capabilities, integrating advanced methodologies and AI platforms. The transaction is expected to close in the second quarter, expanding IQVIA's service offerings in various therapeutic areas.
Read more →IQVIQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
IQVIA and the Duke Clinical Research Institute have announced a strategic collaboration aimed at advancing clinical research in obesity and related conditions. This partnership combines IQVIA's operational capabilities with DCRI's academic expertise to enhance trial efficiency and accelerate the delivery of therapies. With extensive experience in obesity trials, the collaboration is expected to improve patient care and set new benchmarks in clinical research.
Read more →IQVIQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
IQVIA Holdings Inc. reported strong financial results for Q4 and full-year 2025, with revenue growth across all segments. The company achieved near double-digit growth in revenue and earnings per share, and its R&DS contracted backlog grew significantly. For 2026, IQVIA expects continued growth in revenue and adjusted EBITDA, despite anticipated increases in interest expenses.
Read more →IQVIQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
IQVIA has announced a long-term collaboration with Boehringer Ingelheim to enhance its global commercial data capabilities. Utilizing IQVIA’s Data-as-a-Service (DaaS+) platform, Boehringer aims to harmonize its data across various therapeutic areas and regions. This partnership is expected to drive efficiencies in data operations and support upcoming product launches.
Read more →IQVIQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
IQVIA Holdings Inc. will announce its fourth-quarter and full-year 2025 financial results on February 5, 2026. The announcement will be made before market opening, followed by a conference call and webcast at 9:00 a.m. ET. Interested parties must register in advance to participate in the call.
Read more →IQVIQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform
IQVIA has announced a strategic collaboration with Amazon Web Services (AWS), designating AWS as its Preferred Agentic Cloud Provider. This partnership aims to enhance clinical trial automation and healthcare analytics through an innovative AI platform. The collaboration seeks to democratize AI in life sciences, improving drug innovation and patient outcomes globally.
Read more →Competitive Position
How IQV ranks across every disease it competes inCompetitive Position is a premium feature
See how IQV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial